Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Clinical and biological impact of EphA2 overexpression and angiogenesis in endometrial cancer.

Merritt WM, Kamat AA, Hwang JY, Bottsford-Miller J, Lu C, Lin YG, Coffey D, Spannuth WA, Nugent E, Han LY, Landen CN, Nick AM, Stone RL, Coffman K, Bruckheimer E, Broaddus RR, Gershenson DM, Coleman RL, Sood AK.

Cancer Biol Ther. 2010 Dec 15;10(12):1306-14. Epub 2010 Dec 15.

2.

Risk of thromboembolic disease in patients undergoing laparoscopic gynecologic surgery.

Nick AM, Schmeler KM, Frumovitz MM, Soliman PT, Spannuth WA, Burzawa JK, Coleman RL, Wei C, dos Reis R, Ramirez PT.

Obstet Gynecol. 2010 Oct;116(4):956-61. doi: 10.1097/AOG.0b013e3181f240f7.

PMID:
20859161
3.

Regulation of tumor angiogenesis by EZH2.

Lu C, Han HD, Mangala LS, Ali-Fehmi R, Newton CS, Ozbun L, Armaiz-Pena GN, Hu W, Stone RL, Munkarah A, Ravoori MK, Shahzad MM, Lee JW, Mora E, Langley RR, Carroll AR, Matsuo K, Spannuth WA, Schmandt R, Jennings NB, Goodman BW, Jaffe RB, Nick AM, Kim HS, Guven EO, Chen YH, Li LY, Hsu MC, Coleman RL, Calin GA, Denkbas EB, Lim JY, Lee JS, Kundra V, Birrer MJ, Hung MC, Lopez-Berestein G, Sood AK.

Cancer Cell. 2010 Aug 9;18(2):185-97. doi: 10.1016/j.ccr.2010.06.016.

4.

Converging evidence for efficacy from parallel EphB4-targeted approaches in ovarian carcinoma.

Spannuth WA, Mangala LS, Stone RL, Carroll AR, Nishimura M, Shahzad MM, Lee SJ, Moreno-Smith M, Nick AM, Liu R, Jennings NB, Lin YG, Merritt WM, Coleman RL, Vivas-Mejia PE, Zhou Y, Krasnoperov V, Lopez-Berestein G, Gill PS, Sood AK.

Mol Cancer Ther. 2010 Aug;9(8):2377-88. doi: 10.1158/1535-7163.MCT-10-0200. Epub 2010 Aug 3.

5.

Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis.

Sood AK, Armaiz-Pena GN, Halder J, Nick AM, Stone RL, Hu W, Carroll AR, Spannuth WA, Deavers MT, Allen JK, Han LY, Kamat AA, Shahzad MM, McIntyre BW, Diaz-Montero CM, Jennings NB, Lin YG, Merritt WM, DeGeest K, Vivas-Mejia PE, Lopez-Berestein G, Schaller MD, Cole SW, Lutgendorf SK.

J Clin Invest. 2010 May;120(5):1515-23. doi: 10.1172/JCI40802. Epub 2010 Apr 12.

6.

Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer.

Merritt WM, Nick AM, Carroll AR, Lu C, Matsuo K, Dumble M, Jennings N, Zhang S, Lin YG, Spannuth WA, Kamat AA, Stone RL, Shahzad MM, Coleman RL, Kumar R, Sood AK.

Mol Cancer Ther. 2010 Apr;9(4):985-95. doi: 10.1158/1535-7163.MCT-09-0967. Epub 2010 Apr 6.

7.

Farletuzumab in epithelial ovarian carcinoma.

Spannuth WA, Sood AK, Coleman RL.

Expert Opin Biol Ther. 2010 Mar;10(3):431-7. doi: 10.1517/14712591003592069. Review.

PMID:
20092424
8.

Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma.

Merritt WM, Danes CG, Shahzad MM, Lin YG, Kamat AA, Han LY, Spannuth WA, Nick AM, Mangala LS, Stone RL, Kim HS, Gershenson DM, Jaffe RB, Coleman RL, Chandra J, Sood AK.

Cancer Biol Ther. 2009 Aug;8(16):1596-603. Epub 2009 Aug 13.

9.

Therapeutic Targeting of ATP7B in Ovarian Carcinoma.

Mangala LS, Zuzel V, Schmandt R, Leshane ES, Halder JB, Armaiz-Pena GN, Spannuth WA, Tanaka T, Shahzad MM, Lin YG, Nick AM, Danes CG, Lee JW, Jennings NB, Vivas-Mejia PE, Wolf JK, Coleman RL, Siddik ZH, Lopez-Berestein G, Lutsenko S, Sood AK.

Clin Cancer Res. 2009 Jun 1;15(11):3770-80. doi: 10.1158/1078-0432.CCR-08-2306. Epub 2009 May 26.

10.

Estrous cycle modulates ovarian carcinoma growth.

Armaiz-Pena GN, Mangala LS, Spannuth WA, Lin YG, Jennings NB, Nick AM, Langley RR, Schmandt R, Lutgendorf SK, Cole SW, Sood AK.

Clin Cancer Res. 2009 May 1;15(9):2971-8. doi: 10.1158/1078-0432.CCR-08-2525. Epub 2009 Apr 21.

11.

Dicer, Drosha, and outcomes in patients with ovarian cancer.

Merritt WM, Lin YG, Han LY, Kamat AA, Spannuth WA, Schmandt R, Urbauer D, Pennacchio LA, Cheng JF, Nick AM, Deavers MT, Mourad-Zeidan A, Wang H, Mueller P, Lenburg ME, Gray JW, Mok S, Birrer MJ, Lopez-Berestein G, Coleman RL, Bar-Eli M, Sood AK.

N Engl J Med. 2008 Dec 18;359(25):2641-50. doi: 10.1056/NEJMoa0803785. Erratum in: N Engl J Med. 2010 Nov 4;363(19):1877.

12.

Functional significance of VEGFR-2 on ovarian cancer cells.

Spannuth WA, Nick AM, Jennings NB, Armaiz-Pena GN, Mangala LS, Danes CG, Lin YG, Merritt WM, Thaker PH, Kamat AA, Han LY, Tonra JR, Coleman RL, Ellis LM, Sood AK.

Int J Cancer. 2009 Mar 1;124(5):1045-53. doi: 10.1002/ijc.24028.

13.

Tumor-selective response to antibody-mediated targeting of alphavbeta3 integrin in ovarian cancer.

Landen CN, Kim TJ, Lin YG, Merritt WM, Kamat AA, Han LY, Spannuth WA, Nick AM, Jennnings NB, Kinch MS, Tice D, Sood AK.

Neoplasia. 2008 Nov;10(11):1259-67.

14.

Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth.

Lin YG, Immaneni A, Merritt WM, Mangala LS, Kim SW, Shahzad MM, Tsang YT, Armaiz-Pena GN, Lu C, Kamat AA, Han LY, Spannuth WA, Nick AM, Landen CN Jr, Wong KK, Gray MJ, Coleman RL, Bodurka DC, Brinkley WR, Sood AK.

Clin Cancer Res. 2008 Sep 1;14(17):5437-46. doi: 10.1158/1078-0432.CCR-07-4922.

15.

Clinical and biological significance of tissue transglutaminase in ovarian carcinoma.

Hwang JY, Mangala LS, Fok JY, Lin YG, Merritt WM, Spannuth WA, Nick AM, Fiterman DJ, Vivas-Mejia PE, Deavers MT, Coleman RL, Lopez-Berestein G, Mehta K, Sood AK.

Cancer Res. 2008 Jul 15;68(14):5849-58. doi: 10.1158/0008-5472.CAN-07-6130.

16.

HLA class I antigen processing machinery component expression and intratumoral T-Cell infiltrate as independent prognostic markers in ovarian carcinoma.

Han LY, Fletcher MS, Urbauer DL, Mueller P, Landen CN, Kamat AA, Lin YG, Merritt WM, Spannuth WA, Deavers MT, De Geest K, Gershenson DM, Lutgendorf SK, Ferrone S, Sood AK.

Clin Cancer Res. 2008 Jun 1;14(11):3372-9. doi: 10.1158/1078-0432.CCR-07-4433.

17.

Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth.

Merritt WM, Lin YG, Spannuth WA, Fletcher MS, Kamat AA, Han LY, Landen CN, Jennings N, De Geest K, Langley RR, Villares G, Sanguino A, Lutgendorf SK, Lopez-Berestein G, Bar-Eli MM, Sood AK.

J Natl Cancer Inst. 2008 Mar 5;100(5):359-72. doi: 10.1093/jnci/djn024. Epub 2008 Feb 26.

18.

Angiogenesis as a strategic target for ovarian cancer therapy.

Spannuth WA, Sood AK, Coleman RL.

Nat Clin Pract Oncol. 2008 Apr;5(4):194-204. doi: 10.1038/ncponc1051. Epub 2008 Feb 12. Review.

PMID:
18268546
19.

Clinical and biological significance of vascular endothelial growth factor in endometrial cancer.

Kamat AA, Merritt WM, Coffey D, Lin YG, Patel PR, Broaddus R, Nugent E, Han LY, Landen CN Jr, Spannuth WA, Lu C, Coleman RL, Gershenson DM, Sood AK.

Clin Cancer Res. 2007 Dec 15;13(24):7487-95.

20.

Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma.

Halder J, Lin YG, Merritt WM, Spannuth WA, Nick AM, Honda T, Kamat AA, Han LY, Kim TJ, Lu C, Tari AM, Bornmann W, Fernandez A, Lopez-Berestein G, Sood AK.

Cancer Res. 2007 Nov 15;67(22):10976-83. Erratum in: Cancer Res. 2018 Jul 15;78(14):4100.

21.

Neuroendocrine modulation of signal transducer and activator of transcription-3 in ovarian cancer.

Landen CN Jr, Lin YG, Armaiz Pena GN, Das PD, Arevalo JM, Kamat AA, Han LY, Jennings NB, Spannuth WA, Thaker PH, Lutgendorf SK, Savary CA, Sanguino AM, Lopez-Berestein G, Cole SW, Sood AK.

Cancer Res. 2007 Nov 1;67(21):10389-96.

22.

Antitumor and antivascular effects of AVE8062 in ovarian carcinoma.

Kim TJ, Ravoori M, Landen CN, Kamat AA, Han LY, Lu C, Lin YG, Merritt WM, Jennings N, Spannuth WA, Langley R, Gershenson DM, Coleman RL, Kundra V, Sood AK.

Cancer Res. 2007 Oct 1;67(19):9337-45.

23.

Overexpression of the centrosomal protein Aurora-A kinase is associated with poor prognosis in epithelial ovarian cancer patients.

Landen CN Jr, Lin YG, Immaneni A, Deavers MT, Merritt WM, Spannuth WA, Bodurka DC, Gershenson DM, Brinkley WR, Sood AK.

Clin Cancer Res. 2007 Jul 15;13(14):4098-104.

24.

Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway.

Lin YG, Kunnumakkara AB, Nair A, Merritt WM, Han LY, Armaiz-Pena GN, Kamat AA, Spannuth WA, Gershenson DM, Lutgendorf SK, Aggarwal BB, Sood AK.

Clin Cancer Res. 2007 Jun 1;13(11):3423-30.

25.

Concomitant BRCA1 and BRCA2 gene mutations in an Ashkenazi Jewish woman with primary breast and ovarian cancer.

Spannuth WA, Thaker PH, Sood AK.

Am J Obstet Gynecol. 2007 Apr;196(4):e6-9.

PMID:
17403394
26.

The receptor tyrosine kinase EphB4 is overexpressed in ovarian cancer, provides survival signals and predicts poor outcome.

Kumar SR, Masood R, Spannuth WA, Singh J, Scehnet J, Kleiber G, Jennings N, Deavers M, Krasnoperov V, Dubeau L, Weaver FA, Sood AK, Gill PS.

Br J Cancer. 2007 Apr 10;96(7):1083-91. Epub 2007 Mar 13.

27.

A comparison of cisplatin/paclitaxel and carboplatin/paclitaxel in stage IVB, recurrent or persistent cervical cancer.

Moore KN, Herzog TJ, Lewin S, Giuntoli RL, Armstrong DK, Rocconi RP, Spannuth WA, Gold MA.

Gynecol Oncol. 2007 May;105(2):299-303. Epub 2007 Feb 14.

PMID:
17303230
28.

A phase II trial of weekly topotecan for patients with secondary platinum-resistant recurrent epithelial ovarian carcinoma following the failure of second-line therapy.

Spannuth WA, Leath CA 3rd, Huh WK, Barnes MN 3rd, Davidson SA, Kilgore LC, Partridge EE, Austin JM 2nd, Alvarez RD.

Gynecol Oncol. 2007 Mar;104(3):591-5. Epub 2006 Oct 12.

PMID:
17045635
29.

Inflammatory pseudotumor of pelvic lymph nodes.

Spannuth WA, Leath CA 3rd, Conner MG, Alvarez RD.

Obstet Gynecol. 2006 Sep;108(3 Pt 2):779-82.

PMID:
17018500
30.

A comparison of hand-assisted laparoscopy and conventional laparotomy for the surgical evaluation of pelvic masses.

Spannuth WA, Rocconi RP, Huh WK, Straughn JM Jr, Barnes MN 3rd.

Gynecol Oncol. 2005 Nov;99(2):443-6. Epub 2005 Aug 31.

PMID:
16137745
31.

Gamma mode of infiltration associated with poor prognosis in malignant teratoma of the ovary: A case report.

Spannuth WA, Rocconi RP, Kirby TO, Huh WK, Conner MG.

Gynecol Oncol. 2005 Jul;98(1):155-7.

PMID:
15922442

Supplemental Content

Loading ...
Support Center